Bardoxolone巴多索隆,218600-44-3

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bardoxolone

CAS No. : 218600-44-3

MCE 国际站：Bardoxolone

产品活性：Bardoxolone 是一种 新型核调节因子 (Nrf-2)激活剂。

研究领域：NF-κB

作用靶点：Keap1-Nrf2

In Vitro: Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-κB and Janus-activated kinase/STAT signaling. Bardoxolone methyl has been shown to induce differentiation, inhibit proliferation, and induce apoptosis in cancer cell lines.

In Vivo: Kidney sections from Bardoxolone methyl-treated monkeys demonstrates decreased megalin protein expression despite similar mRNA expression across groups. The visualized decrease in megalin protein expression is confirmed by densitometry analyses, which demonstrated that Bardoxolone methyl administration significantly decreased megalin protein expression in the monkey kidney. Bardoxolone methyl administration does not affect the protein expression of cubilin in the kidney or the mRNA expression of cubilin in the kidney. The creatinine clearance in monkeys administered Bardoxolone methyl significantly differed from that at baseline and in vehicle-treated animals on day 28. After 28 days of Bardoxolone methyl administration, urinary albumin-to-creatinine ratios (UACRs), determined from the 24-hour urine collections, are significantly increased compared with those in animals receiving vehicle. Of note, UACRs decreases 53.3% in vehicle-treated animals and increased 27.9% in Bardoxolone methyl-treated monkeys. Male C57BL/6J mice are administered oral BARD during HFD feeding (HFD/BARD), only fed a high-fat diet (HFD), or fed low-fat diet (LFD) for 21 weeks. Compared with LFD mice, HFD mice have a marked increase in the number of F4/80 crown-like structures (+95%; p<0.001), which is effectively prevented by BARD (−50%; p<0.01). Similarly, the number of F4/80 interstitial macrophages is significantly higher in HFD mice by 98% (p<0.001) compared with LFD mice and by 32% (p<0.01) compared with HFD/BARD mice.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antioxidant Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Medicine Food Homology Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Transcription Factor-Targeted Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Mitochondrial Toxicity Compound Library  |  ML385  |  Resveratrol  |  Curcumin  |  4-Octyl itaconate  |  Sulforaphane  |  TBHQ  |  Luteolin  |  Dimethyl fumarate  |  Bardoxolone methyl  |  Omaveloxolone  |  KI696  |  Brusatol  |  Ezetimibe  |  Oltipraz  |  Carnosol  |  Hinokitiol  |  Benzbromarone  |  ML334  |  CBR-470-1  |  Mangiferin  |  Astilbin  |  CDDO-Im  |  Pyridoxine hydrochloride  |  Danshensu  |  NK-252  |  Sappanone A  |  Nrf2-IN-1  |  Safranal  |  Eriodictyol

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds